TY  - GEN
AU  - Santos Bravo, Marta
AU  - Alonso, Rodrigo
AU  - Soria, Dafne
AU  - Sánchez Palomino, Sonsoles
AU  - Sanzo Machuca, Ángela
AU  - Rodríguez, Cristina
AU  - Alcamí, José
AU  - Díez-Fuertes, Francisco
AU  - Simarro Redon, Àlvar
AU  - Hurtado, Juan Carlos
AU  - Fernández Avilés, Francesc
AU  - Bodro, Marta
AU  - Rubio, Elisa
AU  - Villanueva, Jose Luis
AU  - Vergara, Andrea
AU  - Castro, Pedro
AU  - Tuset, Montserrat
AU  - Cuesta, Genoveva
AU  - Puerta, Pedro
AU  - García, Carolina
AU  - Mosquera Gutierrez, Maria del Mar
AU  - Martínez, Miguel J
AU  - Vila, Jordi
AU  - Soriano, Alex
AU  - Marcos, María Ángeles
PY  - 2022
DO  - 10.1128/spectrum.02448-22
UR  - http://hdl.handle.net/20.500.12105/15973
AB  - Remdesivir (RDV) was the first antiviral drug approved by the FDA to treat severe coronavirus disease-2019 (COVID-19) patients. RDV inhibits SARS-CoV-2 replication by stalling the non structural protein 12 (nsp12) subunit of the RNA-dependent RNA...
LA  - eng
PB  - American Society for Microbiology (ASM)
KW  - COVID-19
KW  - Remdesivir
KW  - Resistance mutations
KW  - Subgenomic RNA
KW  - Retreatment
KW  - SARS-CoV-2
KW  - Genetic variants
KW  - SARS-CoV-2
KW  - COVID-19
KW  - Humans
KW  - COVID-19 Drug Treatment
KW  - Adenosine Monophosphate
KW  - Antiviral Agents
TI  - Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir
TY  - research article
ER  -